<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Patients successfully treated for a <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> with cytotoxic therapy have an increased risk of developing secondary <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>We report a patient in remission from <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>) who remains hematologically <z:mpath ids='MPATH_458'>normal</z:mpath> 4 years after combination chemotherapy, but who has biological and genetic abnormalities characteristic of <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>X-inactivation analysis using a 5' phosphoglycerate kinase (PGK) probe demonstrates polyclonal hematopoiesis, but cytogenetic analysis reveals a clonal population with a minority of metaphases having a 7q-deletion </plain></SENT>
<SENT sid="3" pm="."><plain>NRAS mutations are not detectable 1 year after treatment, but are present in two separate clones (at codons 12 and 15) analyzed by single-stranded conformational polymorphism (SSCP), followed by cloning and sequencing 4 years after treatment </plain></SENT>
<SENT sid="4" pm="."><plain>The presence of an activated NRAS with the same codon 12 mutation was independently confirmed by the <z:mp ids='MP_0003815'>nude</z:mp> mouse tumorigenicity assay </plain></SENT>
<SENT sid="5" pm="."><plain>In vitro peripheral blood granulocyte-macrophage colony-forming units (CFU-GM) have changed from <z:mpath ids='MPATH_458'>normal</z:mpath> to undetectable levels while erythroid burst forming units (BFU-E) were significantly reduced on two occasions during the period of observation </plain></SENT>
<SENT sid="6" pm="."><plain>These abnormalities are characteristic of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Continued clinical follow-up will determine whether these evolving genetic and biological abnormalities pre-date the <z:hpo ids='HP_0003674'>onset</z:hpo> of clinical and morphological features of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>